Diagnosis of B-cell non-hodgkin's lymphoma of the central nervous system by immunocytochemical analysis of cerebrospinal fluid lymphocytes

Li, Chin‐Yang ‐Y; Witzig, Thomas E.; Phyliky, Robert L.; Ziesmer, Steven C.; Yam, Lung T.

doi:10.1002/1097-0142(19860215)57:4<737::aid-cncr2820570410>3.0.co;2-6

Cited by 47 publications

(13 citation statements)

References 16 publications

(1 reference statement)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous studies have shown that most CNS lymphomas are of B cell origin by their expression of monotypic Ig [9][10][11][12][13][14][15][16][17][18]. This study extends prior reports by demonstrating that several pan B cell antigens are present on the majority of cases of primary and secondary CNS large cell lymphomas.…”

Section: Discussionsupporting

confidence: 83%

“…The diagnosis of CNS lymphoma can be difficult on routine histologic stains of biopsy material or CSF cytology preparations [9,12]. Recent studies employing antibodies against immunoglobulins (Ig) on paraffin embedded sections [9,11], frozen sections [12,15], and cerebrospinal fluid sediment [16,18] suggest that primary CNS lymphoma consists predominantly of monoclonal B cells. Staining by these antibodies has been shown to be useful in the pathologic diagnosis of these tumors [9][10][11][12][13][14][15][16][17][18].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Immunophenotypic profile of CNS lymphoma: A review of eighteen cases

et al. 1989

View full text Add to dashboard Cite

The cell surface antigenic phenotype of 18 cases of central nervous system (CNS) large-cell lymphoma (14 primary, four secondary) was examined by an immunoperoxidase technique using antibodies that identify B cell restricted and associated antigens. All cases were shown to be of B cell origin by virtue of the expression of monotypic immunoglobulin (Ig) (16 IgM, two IgG) and the pan B cell antigen B1 (CD20). A panel of monoclonal antibodies directed against B cell restricted and associated activation antigens including B5, Blast-1, Blast-2 (CD23), BB1, interleukin 2 receptor (IL2R, CD25), T9 (transferrin receptor) and TNK-TAR (4F2) was used on 12 of the cases. The majority expressed T9 and TNK-TAR. Blast-1 was expressed by less than half the cases and Blast-2 and B5 by one of 12 cases each. This is in contrast to 10 non-CNS diffuse large cell lymphomas where B5 and Blast-1 were present on all cases. This study confirms previous observations that primary CNS large cell lymphomas are of B cell derivation. Moreover, the differences in expression of B cell activation antigens on CNS large cell lymphomas as compared to non-CNS lymphomas raise the possibility that a subset of neoplastic B cells may have unique tropism for the CNS.

show abstract

Section: Discussionsupporting

confidence: 83%

Section: Introductionmentioning

confidence: 99%

Immunophenotypic profile of CNS lymphoma: A review of eighteen cases

et al. 1989

View full text Add to dashboard Cite

show abstract

“…Cytological differentiation between malignant and reactive lymphocytes can be difficult and may lead to falsenegative findings. Moreover, immunohistochemical procedures that have been suggested even if cells appear cytologically benign may give equivocal findings if the immunoglobulins are not produced and expressed on the cell surface [1, 28,45].…”

Section: Discussionmentioning

confidence: 99%

“…Today it is recognised as a high-grade polyclonal or monoclonal malig-nancy with diffuse large cells, immunoblastic cells or lymphoblastic B cells [1,5,24,28,31,44]. Less than 10% of cases are of the T-cell type [1,3,32,34].…”

Section: Introductionmentioning

confidence: 99%

Chemotherapy is effective as early treatment for primary central nervous system lymphoma

Boiardi

Silvani

Pozzi

et al. 1999

Journal of Neurology

View full text Add to dashboard Cite

Primary central nervous system lymphoma (PCNSL) is a lymphoma arising within the brain or spinal cord in the absence of evident localisation outside the central nervous system (CNS). Poor results in the management of relapsed PCNSL justify the need for vigorous initial therapeutic regimens, and chemotherapy should not be reserved for recurrent disease. Chemotherapy (MBACOD scheme) was delivered prior to irradiation in a group of 20 PCNSL patients, another 8 PCNSL patients underwent radiotherapy only, and the overall survival was evaluated. Computed tomography (CT) images in the group of patients treated with chemotherapy, showed there to be 70% complete responders (CR), 15% non-responders (NR) and 15% partial responders (PR). Half of the CR were scheduled for radiotherapy only at tumour recurrence. The median disease-free period and survival time of the whole group treated with early chemotherapy followed by radiotherapy were 24 and 32 months, respectively, but in the subgroup of CR (70%), taking into account also the patients not yet receiving radiotherapy, these were 38 and 48 months, respectively. The disease-free and survival times in the group of CR (75%) of patients treated with radiotherapy only were 13 and 18 months, respectively. At tumour recurrence, CR to chemotherapy had a second disease-free period longer than 2 years after radiotherapy. Our data support the belief that in scheduling the treatment of PCNSL after histological diagnosis, the first step is to devise high-dose chemotherapy with drugs able to cross an intact blood-brain barrier. The results of our primary approach with early chemotherapy in PCNSL support a consensus to continue chemotherapy until tumour recurrence, and only at that event to initiate radiotherapy. It is a challenge and an option worthy of continuing investigation.

show abstract

“…Chronic antigenic stimulation and polyclonal activation of B-cells generally occur, but these patients are unable to control B-cell proliferation [5,6]. Demonstration of specific surface markers [7][8][9] permits immunological characterization of the particular B-cell proliferation involved.…”

Section: Introduction Methodsmentioning

confidence: 99%

Meningitis with Burkitt like B-cell lymphoma in HIV infection

Paz

Kölmel

1992

J Neuro-Oncol

View full text Add to dashboard Cite

Malignant lymphoma with meningeal involvement was detected in 7 patients with stage IV HIV infection. The diagnosis of lymphoma was made at a maximum of four months before discovery of meningeal involvement. In our seven cases the lymphoma was B-cell type, one case expressed Kappa chains, four cases demonstrated Lambda chains and in two cases differentiation was not possible. A review of findings in all HIV positive patients treated in the same period revealed 10 non-Hodgkin lymphomas of the B-cell type, though meningeal and cerebral involvement was observed only in B-cell lymphoma of the Burkitt type.

show abstract

Diagnosis of B-cell non-hodgkin's lymphoma of the central nervous system by immunocytochemical analysis of cerebrospinal fluid lymphocytes

Cited by 47 publications

References 16 publications

Immunophenotypic profile of CNS lymphoma: A review of eighteen cases

Immunophenotypic profile of CNS lymphoma: A review of eighteen cases

Chemotherapy is effective as early treatment for primary central nervous system lymphoma

Meningitis with Burkitt like B-cell lymphoma in HIV infection

Contact Info

Product

Resources

About